Hepatitis C
Research Study
Join a National Institutes of Health research study investigating liver related complications that may occur following cure of hepatitis C infection.
The NIH Clinical Center, in Bethesda, MD
Compensation
Provided
Diagnosed with chronic hepatitis C
In Generally Good Health
At least 18 Years Old
Fast Facts
About this research study:
Help researchers learn more about the course and complications of liver disease that might follow Hepatitis C treatment.
The liver is the largest solid organ that represents the body's major detoxification system. Since the liver is responsible for many critical functions within the body and should it become diseased or injured, the loss of those functions can cause significant damage to the body.

Hepatitis C is one of the most common infections that causes liver inflammation, sometimes leading to serious liver damage. Some people are still experiencing such liver problems as cirrhosis, liver cancer, and other liver-related complications even after the infection has been cured. This National Institutes of Health research study is examining why these complications can occur and ways to prevent them.

Additional Information
Why is this study being done?
Doctors at the National Institute of Diabetes and Digestive and Kidney Diseases are conducting a study to better understand complications that can occur after the hepatitis C virus has been cured. Researchers want to determine why cirrhosis, liver cancer and other liver related complications may occur after treatment.
Is this study for me?
You may qualify for this study if you meet the following criteria.

Eligibility Criteria:
  • At least 18 years of age
  • Diagnosed with chronic hepatitis C at least 6 months ago
  • In good general health
  • Not infected with the HIV virus
  • Not currently pregnant or breastfeeding
What will happen if I participate in the study?
If agreeable, you will undergo screening labs and liver imaging as an outpatient.

If you qualify, you will be admitted for a 3-day stay on a later date to start therapy with sofosbuvir/velpatasvir (Epclusa), an FDA-approved medication for the treatment of hepatitis C.

You will be closely monitored on a monthly basis by an NIH liver physician while on therapy.
Will I be paid for being in this research study?
Compensation might be provided for participation in this study.
Will it cost me anything to participate in this study?
All visits and treatments will be provided at no cost.